BIOTE CORP -A (BTMD) Stock Fundamental Analysis
NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD
Overall BTMD gets a fundamental rating of 6 out of 10. We evaluated BTMD against 195 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, BTMD could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
BTMD had positive earnings in 4 of the past 5 years.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 13.68%, BTMD belongs to the top of the industry, outperforming 95.90% of the companies in the same industry.
The Return On Invested Capital of BTMD (43.56%) is better than 98.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.68% | ||
| ROE | N/A | ||
| ROIC | 43.56% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 6.85%, BTMD belongs to the top of the industry, outperforming 85.13% of the companies in the same industry.
In the last couple of years the Profit Margin of BTMD has declined.
Looking at the Operating Margin, with a value of 16.78%, BTMD belongs to the top of the industry, outperforming 85.64% of the companies in the same industry.
BTMD's Operating Margin has declined in the last couple of years.
BTMD's Gross Margin of 71.27% is fine compared to the rest of the industry. BTMD outperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.78% | ||
| PM (TTM) | 6.85% | ||
| GM | 71.27% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
BTMD has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.94 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.94, BTMD is in the better half of the industry, outperforming 71.79% of the companies in the same industry.
The Debt to FCF ratio of BTMD is 4.81, which is a neutral value as it means it would take BTMD, 4.81 years of fcf income to pay off all of its debts.
BTMD has a better Debt to FCF ratio (4.81) than 84.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.81 | ||
| Altman-Z | 2.94 |
ROIC/WACC4.49
WACC9.71%
2.3 Liquidity
A Current Ratio of 1.42 indicates that BTMD should not have too much problems paying its short term obligations.
The Current ratio of BTMD (1.42) is worse than 69.74% of its industry peers.
A Quick Ratio of 1.14 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD's Quick ratio of 1.14 is on the low side compared to the rest of the industry. BTMD is outperformed by 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 490.91% over the past year.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
The Revenue has grown by 31.42% in the past year. This is a very strong growth!
Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 48.92% on average per year.
The Revenue is expected to grow by 9.89% on average over the next years. This is quite good.
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 6.28, which indicates a rather cheap valuation of BTMD.
Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 95.38% of the companies listed in the same industry.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.28, the valuation of BTMD can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 85.64% of the companies listed in the same industry.
BTMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.28 | ||
| Fwd PE | 8.28 |
4.2 Price Multiples
89.74% of the companies in the same industry are more expensive than BTMD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 96.92% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.64 | ||
| EV/EBITDA | 7.72 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 49.45% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y49.45%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.08
-0.13 (-3.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners66.3%
Inst Owner Change0%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap206.49M
Analysts83.33
Price Target6.8 (66.67%)
Short Float %2.99%
Short Ratio5.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)228.05%
Min EPS beat(2)-1.96%
Max EPS beat(2)458.07%
EPS beat(4)2
Avg EPS beat(4)111.48%
Min EPS beat(4)-269.68%
Max EPS beat(4)458.07%
EPS beat(8)4
Avg EPS beat(8)19.41%
EPS beat(12)6
Avg EPS beat(12)-81.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.66%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)3
Avg Revenue beat(8)-1.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.05%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.74%
PT rev (3m)-10.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.24%
EPS NY rev (1m)4.57%
EPS NY rev (3m)52.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.28 | ||
| Fwd PE | 8.28 | ||
| P/S | 0.84 | ||
| P/FCF | 5.64 | ||
| P/OCF | 4.66 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.72 |
EPS(TTM)0.65
EY15.93%
EPS(NY)0.49
Fwd EY12.08%
FCF(TTM)0.72
FCFY17.72%
OCF(TTM)0.88
OCFY21.47%
SpS4.86
BVpS-1.78
TBVpS-2.07
PEG (NY)0.03
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.68% | ||
| ROE | N/A | ||
| ROCE | 55.13% | ||
| ROIC | 43.56% | ||
| ROICexc | 98.25% | ||
| ROICexgc | 177.09% | ||
| OM | 16.78% | ||
| PM (TTM) | 6.85% | ||
| GM | 71.27% | ||
| FCFM | 14.86% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.81 | ||
| Debt/EBITDA | 3.22 | ||
| Cap/Depr | 210.54% | ||
| Cap/Sales | 3.15% | ||
| Interest Coverage | 4.43 | ||
| Cash Conversion | 98.57% | ||
| Profit Quality | 216.82% | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.94 |
F-Score6
WACC9.71%
ROIC/WACC4.49
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
EBIT growth 1Y32.35%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y19.2%
FCF growth 1Y849.75%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y1512.04%
OCF growth 3Y10.29%
OCF growth 5Y12.28%